December 20, 2022

Entrada Therapeutics Announces Clinical Hold on IND Application for ENTR-601-44 in Duchenne

Entrada Therapeutics has shared that the FDA issued a clinical hold on the Investigational New Drug (IND) application for its ENTR-601-44 program, an exon-skipping therapy set to target individuals with Duchenne amenable to exon 44…

Learn More

December 19, 2022

WATCH: A Conversation with PTC Therapeutics (Webinar Recording)

WATCH: A Conversation with PTC Therapeutics (Webinar Recording) PTC Therapeutics recently joined PPMD for a community webinar on Friday, December 9, 2022 for a discussion regarding PTC’s history with the community and plans for the…

Learn More

December 12, 2022

The Duchenne Registry Celebrates 15 Years of Data Collection

The PPMD team is incredibly grateful for the families who have shared their Duchenne and Becker experience with The Duchenne Registry over the years. It is hard to believe that the first families joined the…

Learn More

December 6, 2022

Complete Your Registry Surveys and You Could Win Your Choice of a $150 Holiday Gift Card!

It’s the Holiday Season and we are thrilled to have another great raffle for families who participate in The Duchenne Registry! This December, the Registry will be giving away TWO $150 e-gift cards to the…

Learn More

December 5, 2022

Solid Biosciences Announces Completion of AavantiBio Acquisition & Update on Duchenne Pipeline Program

Today Solid Biosciences shared an update with the Duchenne community regarding their strategic development. Solid announced they have completed the acquisition of AavantiBio, a gene therapy company. The combined company will focus on advancing a…

Learn More

November 28, 2022

Sarepta Announces Biologics License Application (BLA) Accepted For Filing by the FDA for SRP-9001

PPMD is thrilled to learn that the FDA has accepted for filing and granted priority review for the Biologics License Application (BLA) for Sarepta’s gene therapy product, SRP-9001 (delandistrogene moxeparvovec) for the treatment of ambulant…

Learn More

November 21, 2022

PTC Shares Community Letter Updating on Activities To Bring Ataluren (Translarna) To US Patients

PTC Therapeutics has shared a community letter updating on the company’s activities to bring ataluren (Translarna) to US patients with nonsense mutations. PPMD will host a community webinar with PTC on Friday, December 9th at…

Learn More

November 18, 2022

Pfizer Announces First Participant Dosed in DAYLIGHT Phase 2 Gene Therapy Trial

Pfizer has announced that the first participant has been dosed in the Phase 2 DAYLIGHT study, which will evaluate the safety and tolerability of the company’s investigational mini-dystrophin gene therapy product (fordadistrogene movaparvovec) in very young…

Learn More

November 8, 2022

Astellas Announces Decision to Discontinue Screening & Enrollment Activities for ASP0367 (MA-0211)

PPMD is disappointed to learn that Astellas has announced its decision to discontinue further screening and enrollment activities for ASP0367 (MA-0211) in participants with Duchenne. This decision was not based on safety concerns, but due…

Learn More

November 7, 2022

Astellas Announces Decision to Discontinue Screening & Enrollment Activities for ASP0367 (MA-0211)

PPMD is disappointed to learn that Astellas has announced its decision to discontinue further screening and enrollment activities for ASP0367 (MA-0211) in participants with Duchenne. This decision was not based on safety concerns, but due…

Learn More